Skip to main content
. 2021 Dec 3;13(23):6092. doi: 10.3390/cancers13236092

Figure 2.

Figure 2

Neoantigen profile and immune signatures (n = 60). (A) Tumor mutation burden at initial diagnosis and recurrence in IDH-mutant (MT) and IDH-wildtype (WT) gliomas. (B) A significant correlation between expressed neoantigens and tumor mutation burden in all samples (R = 0.52, p < 0.0001. (C) An inverse correlation between TMB and immune score in IDH-wildtype glioma samples (R = −0.46, p < 0.05). (D) No correlation between TMB and immune score in IDH-mutant samples (R = 0.04, p > 0.05). (E) Heatmap of immune signatures in gliomas. Samples are grouped by their IDH mutation status and HMP status. Expressed neo, expressed neoantigen. ns: not statistically significant, *, p < 0.05; **, p < 0.01; ****, p < 0.0001. WT-ND, IDH-wildtype, newly diagnosed tumor. WT-R, IDH-wildtype, recurrent tumor. MT-ND, IDH-mutant, newly diagnosed tumor. MT-R, IDH-mutant, recurrent tumor. Wilcoxon rank sum test, ns: not statistically significant; *, p < 0.05.